Application of oral inorganic iodine in the treatment of Graves' disease
- PMID: 37077352
- PMCID: PMC10106709
- DOI: 10.3389/fendo.2023.1150036
Application of oral inorganic iodine in the treatment of Graves' disease
Abstract
Iodine is a crucial trace element for the human body and the basic raw material for the synthesis of thyroid hormones. Oral inorganic iodine includes dietary iodine and therapeutic iodine, both of which are closely associated with thyroid immunity and metabolism. Graves' disease (GD), also known as diffuse toxic goiter, is characterized by hyperthyroidism and high iodine metabolism. Clinically, patients diagnosed with GD are often asked to limit iodine intake or even avoid iodine in their diet. The latest research has demonstrated that the interference of dietary iodine with antithyroid drugs (ATDs) treatment may be overestimated. In addition, as a medication for GD treatment, the administration of inorganic iodine has shown positive results in patients with mild hyperthyroidism, a low thyroid autoantibody concentration, a small thyroid volume, a high iodine diet and so on. Inorganic iodine may also be used as an alternative when patients experience side effects with traditional ATDs and for those who still prefer conservative treatment. Due to its low teratogenicity, blood toxicity and bone marrow toxicity, inorganic iodine plays a unique role in special populations, such as pregnant or lactating patients and patients receiving tumor radiotherapy or chemotherapy. In this review, the research progress, biological function, doses and effects, applicable populations and specific applications of dietary iodine and therapeutic iodine are summarized to provide references for the diagnosis and treatment of GD, thus improving the quality of life of GD patients.
Keywords: Graves’ disease; diet; inorganic iodine; special population; therapy.
Copyright © 2023 Huang, Xu, Xu, Zhao and Chen.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Management of urinary stones by experts in stone disease (ESD 2025).Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Iodine supplementation for women during the preconception, pregnancy and postpartum period.Cochrane Database Syst Rev. 2017 Mar 5;3(3):CD011761. doi: 10.1002/14651858.CD011761.pub2. Cochrane Database Syst Rev. 2017. PMID: 28260263 Free PMC article.
-
Effect of iodine nutritional status on the recurrence of hyperthyroidism and antithyroid drug efficacy in adult patients with Graves' disease: a systemic review.Front Endocrinol (Lausanne). 2023 Oct 11;14:1234918. doi: 10.3389/fendo.2023.1234918. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37900151 Free PMC article.
-
Radioiodine therapy versus antithyroid medications for Graves' disease.Cochrane Database Syst Rev. 2016 Feb 18;2(2):CD010094. doi: 10.1002/14651858.CD010094.pub2. Cochrane Database Syst Rev. 2016. PMID: 26891370 Free PMC article.
Cited by
-
Sex-Related Differences in Risk Factors Associated With Nonhealing or Recurrence of Hyperthyroidism in Patients With Graves' Disease Treated With Radioactive Iodine.Health Care Sci. 2025 Jun 13;4(3):188-194. doi: 10.1002/hcs2.70021. eCollection 2025 Jun. Health Care Sci. 2025. PMID: 40568628 Free PMC article.
-
Possible molecular exploration of herbal pair Haizao-Kunbu in the treatment of Graves' disease by network pharmacology, molecular docking, and molecular dynamic analysis.Front Endocrinol (Lausanne). 2023 Oct 4;14:1236549. doi: 10.3389/fendo.2023.1236549. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37859983 Free PMC article.
-
Therapeutic effectiveness of iodine-rich herbs in treating Graves' hyperthyroidism: a retrospective cohort study from a single center.Front Endocrinol (Lausanne). 2025 Aug 11;16:1573617. doi: 10.3389/fendo.2025.1573617. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40862118 Free PMC article. Clinical Trial.
-
Role of Lugol solution before total thyroidectomy for Graves' disease: randomized clinical trial.Br J Surg. 2024 Aug 2;111(8):znae196. doi: 10.1093/bjs/znae196. Br J Surg. 2024. PMID: 39129619 Free PMC article. Clinical Trial.
-
Iodinated contrast media (ICM)-induced thyroid dysfunction: a review of potential mechanisms and clinical management.Clin Exp Med. 2025 Apr 29;25(1):132. doi: 10.1007/s10238-025-01664-5. Clin Exp Med. 2025. PMID: 40299149 Free PMC article. Review.
References
-
- Noh JY, Chino T, Ito K. Treatment with inorganic iodine for graves' hyperthyroidism. Nihon Rinsho (2006) 64(12):2269–73. - PubMed
-
- Yoshihara A, Noh JY, Watanabe N, Kunii Y, Suzuki M, Matsumoto M, et al. . Characteristics of patients with graves' disease whose thyroid hormone levels increase after substituting potassium iodide for methimazole in the first trimester of pregnancy. Thyroid (2020) 30(3):451–6. doi: 10.1089/thy.2019.0392 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources